American College of Clinical Pharmacy
      Search      Cart
         

PedSAP 2025


Format to Purchase:
Member Price:
$88.00
Nonmember Price:
$132.00

Available for ACPE CREDIT ONLY

ASHP members, please call (913)492-3311 to receive multi-book discounts at the member rate. Your ASHP membership number and expiration date are required.

The latest release in ACCP’s popular Pediatric Self-Assessment Program (PedSAP) features comprehensive reviews, timely evidence-based updates, and case series on various topics relating to neonatal and pediatric intensive care, along with the management of specific disorders that may occur in this setting. The target audience for PedSAP 2025 is board-certified and advanced-level clinical pharmacists caring for critically ill neonatal and/or pediatric patients, as well as pharmacists who are involved in parenteral nutrition and/or anticoagulation management.

Faculty Panel Chair Michael J. Raschka, Pharm.D., BCPPS, DPLA
Raschka

The book contains nine learning elements offering a total of 20.5 available continuing pharmacy education (CPE) and/or BCPPS recertification credits. Each learning activity may be taken individually for CPE credit. Content was developed under the leadership of Faculty Panel Chair Michael J. Raschka, Pharm.D., BCPPS, DPLA, Clinical Pharmacy Coordinator and Residency Program Director (PGY1), Children’s Minnesota, Minneapolis and St. Paul, Minnesota.

Continuing education activities in PedSAP cover the most recent published data (past 3–5 years) on a specific therapeutic area or patient-care problem. Learning content is provided as an electronic book (interactive PDF) with high-level updates in up to three formats, as appropriate to the topic:

  • Traditional chapters reviewing the latest published evidence on a therapeutic or practice-related topic
  • Case-series (each section of learning content is bookended by a sample case and its explained answer)
  • Recorded webcast (a PowerPoint presentation provided as an MP4 file as well as a PDF of slides and transcribed narrative)

Every PedSAP release comes in two full-color online formats: (1) interactive PDFs you can save to your desktop or print; and (2) an e-media version you can view on an e-reader, tablet, iOS or Android smart phone.

All PedSAP learning elements are fully referenced, with clickable hyperlinks to literature compilers such as PubMed. Other links provide ready access to clinical practice guidelines, official recommendations, and patient assessment tools. Graphic features focus on pivotal studies, patient care scenarios, and take-home points that can be readily integrated into clinical practice.

Release Date: July 15, 2025
BCPPS Deadline: July 15, 2026
ACPE Deadline: July 15, 2028

Editor(s): Lee BR, Ohler KH
Publication Year: 2025
Format: PDF and ePub

Contents

Chapter: Analgesia and Sedation

On an annual basis in the United States, about 30 million children visit an ED and about two million pediatric patients require admission to the hospital (Newgard 2023; Weiss 2022). Within the surgical space, an annual average of 3.9 million surgeries are performed on pediatric patients, with about 450,000 of those procedures requiring admission to the hospital (Rabbitts 2020). During the course of hospitalization, a significant percentage of pediatric patients experience pain.

Chapter: Sepsis

Sepsis is a complex clinical syndrome characterized by a dysregulated and disproportionate response to an infection by the host’s immune system leading to shock and end-organ failure if not treated promptly. As the most common cause of in-hospital mortality in the United States, a 2017 estimate indicates an annual global incidence of 25.2 million cases of sepsis in patients age 19 years and younger, with 20.3 million of these cases occurring in patients younger than 5 years (Rudd 2020). Pediatric survivors of sepsis commonly experience physical, cognitive, and emotional disabilities resulting in a decline in their
overall quality of life (Carlton 2022; Zimmerman 2020). These disabilities can persist, often for longer than 1 year, and can affect family and caregivers as well. In 2017, WHO recognized sepsis as a global health priority and adopted a resolution for improving the prevention, diagnosis, and management of sepsis (Fleischmann-Struzek 2018; Reinhart 2017). The resolution leans on criteria to accurately identify and define patients with infection who are at high risk of developing sepsis and septic shock. Until recently, high-quality, well-defined diagnostic criteria for sepsis were lacking for the pediatric population.

Chapter: Pulmonary Hypertension

Pediatric pulmonary hypertension (PH) is a rare, progressive disease characterized by increased pulmonary artery pressure, which can eventually lead to right ventricular dysfunction and failure. It is associated with a poor prognosis if not diagnosed or treated appropriately. The goals of treating this disease include slowing disease progression, alleviating symptoms, and improving quality of life.

Chapter: Hyponatremia

Hyponatremia is the most common electrolyte imbalance found and analyzed in the medical literature (Gross 2012). Often found incidentally on routine laboratory tests or on ED or hospital admission, the exact incidence of hyponatremia is unknown and thought to be underreported. Current literature estimates a rate of 15%-30% among adult acute or chronic hospital admissions (Verbalis 2013). Hyponatremia is either responsible for or an accessory finding during an estimated 15%-20% of adult ED visits (Ball 2018). Of all cases of hyponatremia in adults, 40%-75% are hospital-acquired or iatrogenic (Verbalis
2013). In pediatric patients, the overall incidence on admission is estimated as 17%-45%, with hyponatremia occurring in 20%-35% of admitted patients (Jones 2018). Hyponatremia accounts for or is identified within 17.6% of pediatric ED visits and 67.2% of pediatric ICU admissions (Saba 2024). On par with adult epidemiology, 77% of pediatric patients admitted for hyponatremia had a chronic illness (Jones 2018). The etiology of hyponatremia is multifactorial and can be present in patients with hypovolemia, euvolemia, and hypervolemia. Hyponatremia can further be classified by serum osmolality as hypotonic, hypertonic, or isotonic (Saba 2024).

Chapter: Total Parenteral Nutrition

Malnutrition is an important medical issue in both pediatric ICUs (PICUs) and neonatal ICUs (NICUs). The incidence of malnutrition in the PICU in one study was 20%. In the same study, when patients who were malnourished were compared with patients who were not, malnourished patients had longer length of stay and higher readmission rates at 30 days (Khlevner 2023). Growth failure in very low birth weight infants is clinically challenging, with up to 97% of infants weighing less than the 10th percentile at 36 weeks corrected age (Dusick 2003).

Chapter: Direct Oral Anticoagulant Use

Incidence of VTE in hospitalized children increased to 34 to 58 cases per 10,000 hospital admissions from 2001 to 2007 (Raffini 2009). Over one-half of subjects (57%) were in an ICU (neonatal, pediatric, or cardiac) at the time of VTE diagnosis, and the median time to diagnosis was 10 days after admission (interquartile range, 5-20 days). In a follow-up study over the next 12 years, VTE cases increased from 46 to 106 per 10,000 admissions (O’Brien 2022). As a result, more children are treated with anticoagulants, and a growing number are treated with direct oral anticoagulants (DOACs). Newer data have led to changes in anticoagulation guidelines suggesting there is no benefit or increased risk of harm in providing anticoagulation in some specific scenarios of trauma and central venous catheter–associated VTE (van Ommen 2023). The Institute for Safe Medication Practices considers all antithrombotic agents in an acute care setting to be highalert medications (Institute for Safe Medication Practices 2025). Even though DOACs have reduced laboratory monitoring and drug interactions compared with traditional anticoagulants, it is important for the clinical pharmacist not to lose sight of indications and safety. From a national public health surveillance system, the frequency of ED visits for DOAC-related bleeding increased by 27.9% per year from 2016 to 2020 (Geller 2023). One-third of all bleeding events had an association with concomitant medications, leading the authors to suggest improved appropriate prescribing and monitoring for anticoagulation.

Case Series: Enteral Tube Medication Administration

Enteral tubes are used in pediatric patients for many reasons, including placement for acute care provided over several days and chronic care over months to years. Their use has been increasing over the past several years; thus, it is important for pharmacists to be familiar with the types of tubes available and how medication administration is affected by the use of enteral tubes.

Case Series: Illicit Drug Toxicology

Acute intoxication accounts for approximately 5% of PICU admissions annually (Patel 2017). The etiology of these overdoses includes unintentional, exploratory ingestions in young children and intentional recreational or self-harm exposures in older children and adolescents. Commonly used illicit substances include cannabis, opioids, stimulants, inhalants, and psychedelics.

Case Series: Kidney Replacement Therapies

Kidney replacement therapies (KRT) are used in children with end-stage kidney disease (ESKD) and severe AKI to remove waste products and fluid when the kidney is unable to adequately do so. The choice of KRT modality varies by setting. In the acute setting, KRT modalities include continuous kidney replacement therapy (CKRT) and prolonged intermittent kidney replacement therapy (PIKRT). Intermittent hemodialysis (IHD) and peritoneal dialysis (PD) may be used acutely or chronically. Kidney transplant is a long-term form of KRT that may be performed either preemptively (ie, before long-term dialysis is needed), or after initiation of long-term dialysis in patients with kidney failure. For children who weigh less than 10 kg, kidney transplantation is uncommon because of both technical and physiologic challenges although it may be feasible in select centers with relevant expertise (Weitz 2018). When possible, preemptive kidney transplantation is preferred because this approach can avoid the morbidity and mortality associated with dialysis. In addition, preemptive kidney transplantation has been associated with decreases in acute rejection and graft loss in all pediatric kidney transplant recipients, as well as decreased mortality in living-donor recipients (Magar 2022; McDonald 2004). This chapter will focus exclusively on non-transplant KRT options.

Chapter: Analgesia and Sedation

Faculty

Jennifer L. Placencia, Pharm.D., MS, BCPPS

Clinical Pharmacy Specialist – Pain, Palliative Care, Opioid Stewardship
Department of Pharmacy
Texas Children’s Hospital
Instructor
Department of Pediatrics
Baylor College of Medicine
Houston, Texas

Katherine I. Lemming, Pharm.D., BCPPS

Clinical Pharmacy Specialist – Pediatric and Adult Heart Center Services
Department of Pharmacy
Texas Children’s Hospital
Instructor
Department of Pediatrics – Critical Care
Baylor College of Medicine
Houston, Texas

Reviewers

Emma L. Ross, Pharm.D., BCPPS

Clinical Pharmacy Specialist, NICU/L+D
Department of Pharmacy
Children’s Hospital Colorado
Aurora, Colorado

Lauren Oliveri, Pharm.D., BCPPS

Clinical Assistant Professor
Clinical Pharmacist, Pediatrics
Department of Pharmacy Practice
University of Illinois Chicago
Chicago, Illinois

Chapter: Sepsis

Faculty

Melissa A. Cook, Pharm.D., BCPPS

Clinical Pharmacy Manager
Residency Program Director (PGY1)
Department of Pharmacy
Manning Family Children’s
New Orleans, Louisiana

Michael J. Raschka, Pharm.D., BCPPS, DPLA

Clinical Pharmacy Coordinator
Residency Program Director (PGY1)
Children’s Minnesota
Minneapolis, Minnesota

Reviewers

Erin Neumann, Pharm.D., BCPPS

PICU Pharmacist
Department of Pharmacy
Children’s Minnesota
Minneapolis, Minnesota

Boh Song, Pharm.D., BCPPS

PICU Clinical Pharmacy Specialist
Division of Pharmacy
Children’s National Hospital
Washington, District of Columbia

Chapter: Pulmonary Hypertension

Faculty

Neelam D. Bhatt, Pharm.D., BCPPS

Clinical Pharmacy Specialist, Lung Transplant/Pulmonary Hypertension
Department of Pharmacy
Texas Children’s Hospital
Houston, Texas

Duong T. Nguyen, Pharm.D.

Clinical Pharmacy Specialist – Neonatology
Department of Pharmacy
Texas Children’s Hospital
Houston, Texas

Reviewers

Kimberley W. Benner, Pharm.D., BCPS

Professor of Pharmacy Practice
Department of Pharmacy Practice
Samford University McWhorter School of Pharmacy
Homewood, Alabama

Jesse Cramer, Pharm.D., BCPPS

Manager, Clinical Pharmacy Services
Department of Pharmacy
Children’s Wisconsin
Clinical Assistant Professor
Department of Clinical Sciences
Medical College of Wisconsin School of Pharmacy
Milwaukee, Wisconsin

Jillian Grapsy, Pharm.D., BCPPS

Clinical Pharmacy Specialist, Pediatric Intensive Care
Department of Pharmacy
Children’s Health – Children’s Medical Center Dallas
Dallas, Texas

Chapter: Hyponatremia

Faculty

Elisa Edwards, Pharm.D., BCPS, BCPPS

Pediatric Critical Care Clinical Supervisor
Department of Pharmacy
OHSU Doernbecher Children’s Hospital
Portland, Oregon

Reviewers

Aaron Harthan, Pharm.D., BCPPS

Pediatric Critical Care Pharmacist
Department of Clinical Pharmacy
OSF Healthcare Children’s Hospital of Illinois
Peoria, Illinois

Airka Sanchez, Pharm.D., BCPPS

Pediatric Clinical Pharmacist
Department of Pharmacy
St. Joseph’s Children’s Hospital
Tampa, Florida

Chapter: Total Parenteral Nutrition

Faculty

Francine Breckler, Pharm.D., BCPPS

Clinical Pharmacist, Pediatric General Surgery/Gastroenterology
Department of Pharmacy
Riley Hospital for Children
Indianapolis, Indiana

Jontae Warren, Pharm.D., BCPPS

Neonatal ICU Clinical Pharmacy Specialist
Department of Pharmacy
Ochsner Medical Center
New Orleans, Louisiana

Reviewers

Elaina E. Szeszycki, Pharm.D., CNSC

Clinical Pharmacist
Department of Pharmacy
Riley Hospital for Children, IU Health
Indianapolis, Indiana

Venus Nguyen, Pharm.D., BCPPS, BCCCP, BCPS

Clinical Pharmacist
Department of Pharmacy
Joe DiMaggio Children’s Hospital
Hollywood, Florida

Lois Lee, Pharm.D., BCPPS, BCIDP

Clinical Pharmacy Specialist
Department of Pharmacy
Inova Fairfax Medical Campus
Falls Church, Virginia

Chapter: Direct Oral Anticoagulant Use

Faculty

Timothy Q. Schardt, Pharm.D., BCPS

Clinical Pharmacy Specialist, Anticoagulation
Department of Pharmacy
Children’s Hospital Colorado
Aurora, Colorado

Reviewers

Norman E. Fenn, III, Pharm.D., FASHP, BCPS, BCPPS

Clinical Associate Professor
Department of Pharmacy Practice
Manchester University College of Pharmacy & Health Sciences
Pediatric Clinical Pharmacist
Department of Pharmacy
Parkview Women’s and Children’s Hospital
Fort Wayne, Indiana

Ezinwanne Rosemary Emelue, Pharm.D., BCPPS

Clinical Pharmacist Specialist
Department of Pharmacy
St. Louis Children’s Hospital
Saint Louis, Missouri

Case Series: Enteral Tube Medication Administration

Faculty

Rachel Meyers, Pharm.D., FPPA, BCPS, BCPPS

Clinical Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy, Rutgers University
Piscataway, New Jersey
Pediatric Clinical Pharmacist
Pharmacy Department
Cooperman Barnabas Medical Center
Livingston, New Jersey

Reviewers

Stephanie Mohan, Pharm.D., BCPPS, BCPS

Emergency Medicine Clinical Pharmacist
Department of Pharmacy
Children’s Hospital of Minnesota – Minneapolis
Minneapolis, Minnesota

Jessica Frye, Pharm.D., BCPPS

Clinical Pharmacy Manager, Pediatric Critical Care
Department of Pharmacy
Mount Sinai Hospital
New York, New York

Case Series: Illicit Drug Toxicology

Faculty

Emily Jaynes Winograd, Pharm.D., DABAT

Pediatric Clinical Pharmacist Specialist
Department of Pharmacy
Michigan Medicine
Ann Arbor, Michigan

Reviewers

Dawn R. Sollee, Pharm.D., FAACT, DABAT

Director
Florida/USVI Poison Information Center – Jacksonville
Clinical Professor
Department of Emergency Medicine
University of Florida College of Medicine and UF Health
Jacksonville, Florida

Maren Pope, Pharm.D., BCPPS

Pediatric Clinical Pharmacist
Critical Care (NICU, PICU, CVICU)
Children’s Minnesota
Minneapolis, Minnesota

Stephanie Weightman, Pharm.D., BCPS, BCPPS, BCEMP

Clinical Pharmacist
Department of Pharmacy
Regional One Health
Memphis, Tennessee

Case Series: Kidney Replacement Therapies

Faculty

Elizabeth A.S. Goswami, Pharm.D., BCPS, BCPPS

Clinical Pharmacy Specialist
Department of Pharmacy
The Johns Hopkins Hospital
Baltimore, Maryland

Reviewers

Cynthia Toy, Pharm.D., BCPPS

Clinical Pharmacy Specialist
Department of Pharmacy
Texas Children’s Hospital
Houston, Texas

Christine Tabulov, Pharm.D., BCPPS

Assistant Professor
Pharmacotherapeutics and Clinical Research
University of South Florida Taneja College of Pharmacy
Tampa, Florida

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Target Audience: The target audience for PedSAP 2025 is board-certified and advanced-level clinical pharmacists caring for critically ill neonatal and/or pediatric patients, as well as pharmacists who are involved in parenteral nutrition and/or anticoagulation management.

Contents

Chapter: Analgesia and Sedation

Activity Number: 0217-9999-25-158-H01-P
Contact Hour(s): 2.50
Activity Type: Application Based
Learning Objectives

1. Distinguish between the different types of analgesia and sedation in a pediatric patient.
2. Apply the appropriate analgesia and sedation scale based on patient characteristics.
3. Evaluate the latest analgesia and sedation guidelines and their applicability to the pediatric patient population.
4. Demonstrate understanding of medications used for analgesia and sedation and their effects on neurodevelopment.
5. Assess the challenges associated with managing analgesia and sedation in the pediatric patient.

Chapter: Sepsis

Activity Number: 0217-9999-25-165-H01-P
Contact Hour(s): 2.00
Activity Type: Application Based
Learning Objectives

1. Assess current consensus criteria for identifying pediatric sepsis and septic shock.
2. Evaluate available screening tools used to promote early recognition of pediatric sepsis.
3. Analyze the role of balanced crystalloid fluids in pediatric patients with septic shock or sepsis-associated organ dysfunction.
4. Devise empiric antimicrobial therapy regimens for pediatric patients with suspected sepsis and septic shock.
5. Evaluate vasoactive and inotrope medications, as well as adjunct and advanced therapies for managing fluid-refractory and catecholamine-resistant shock in pediatric patients.
6. Justify the implementation of sepsis bundles at the institutional and caregiver level to improve patient outcomes.

Chapter: Pulmonary Hypertension

Activity Number: 0217-9999-25-164-H01-P
Contact Hour(s): 3.00
Activity Type: Application Based
Learning Objectives

1. Distinguish the pathophysiology, diagnosis, evaluation, and classification of pediatric pulmonary hypertension.
2. Analyze current guideline recommendations for pulmonary hypertension management.
3. Evaluate treatment targeting several pathways of pulmonary hypertension and its place in therapy.
4. Classify upcoming novel medication therapy options with specific mechanisms of action.

Chapter: Hyponatremia

Activity Number: 0217-9999-25-161-H01-P
Contact Hour(s): 3.00
Activity Type: Application Based
Learning Objectives

1. Distinguish between the causes of and the differential diagnoses of hyponatremia in pediatric patients.
2. Devise a plan for sodium replacement therapy in pediatric patients with syndrome of inappropriate antidiuretic hormone secretion.
3. Evaluate the role and place in therapy of conivaptan and tolvaptan in pediatric patients.
4. Design a plan for managing serum sodium correction with current therapies in pediatric patients.

Chapter: Total Parenteral Nutrition

Activity Number: 0217-9999-25-166-H01-P
Contact Hour(s): 2.50
Activity Type: Application Based
Learning Objectives

1. Apply an understanding of clinical guideline updates to the pediatric and neonatal populations.
2. Assess the differences between injectable lipid emulsion (ILE) products, and recommend appropriate interventions for the prevention or treatment of essential fatty acid deficiency (EFAD) and intestinal failure–associated liver disease (IFALD).
3. Demonstrate knowledge of hypertriglyceridemia management in parenteral nutrition (PN) and place in therapy for carnitine supplementation.
4. Distinguish which trace metal product is appropriate given specific patient parameters.
5. Apply knowledge of factors affecting the solubility of calcium and phosphorus in PN to prevent or reduce risk of precipitation.

Chapter: Direct Oral Anticoagulant Use

Activity Number: 0217-9999-25-159-H01-P
Contact Hour(s): 2.00
Activity Type: Application Based
Learning Objectives

1. Justify the role and place for standard of care anticoagulants and direct oral anticoagulants (DOACs).
2. Distinguish differences among DOACs that affect safety and efficacy.
3. Devise a management plan for anticoagulant therapy in pediatric patients around procedures and bleeding.
4. Detect circumstances in which DOAC use is not favorable in pediatric patients.

Case Series: Enteral Tube Medication Administration

Activity Number: 0217-9999-25-160-H01-P
Contact Hour(s): 1.00
Activity Type: Application Based
Learning Objectives

1. Assess a pediatric patient for appropriateness of an enteral feeding tube.
2. Classify the appropriateness of a medication for enteral tube administration based on the medication’s properties, the type of enteral tube, and the location of the feeding tube’s distal end.
3. Compose a plan for appropriate administration of medications through an enteral feeding tube, including dose preparation and flushing procedures.
4. Develop strategies to reduce the risk of clogging enteral tubes while administering medications.

Case Series: Illicit Drug Toxicology

Activity Number: 0217-9999-25-162-H01-P
Contact Hour(s): 1.50
Activity Type: Application Based
Learning Objectives

1. Evaluate the symptoms of cannabis exposure in a young child versus an adolescent.
2. Distinguish between cannabis toxicity and synthetic cannabinoid toxicity.
3. Assess the role of naloxone in the management of sedative toxicity.
4. Apply diagnostic criteria for serotonin toxicity to a patient case.
5. Devise an acute treatment plan for a pediatric patient presenting with 3,4-methylenedioxymethamphetamine toxicity.

Case Series: Kidney Replacement Therapies

Activity Number: 0217-9999-25-163-H01-P
Contact Hour(s): 3.00
Activity Type: Application Based
Learning Objectives

1. Distinguish the differences in indications among various forms of kidney replacement therapy (KRT) in pediatric patients.
2. Assess the effects of KRT on medication dosing in pediatric patients.
3. Estimate the level of residual kidney function in a pediatric patient receiving KRT.
4. Devise a medication dosing plan for a pediatric patient receiving KRT.

Disclosures


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.